A single-blind placebo controlled study. The aim of this study was to evaluate the efficacy to felodipine, a long-acting calcium antagonist, in patients mild to moderate essential hypertension. The study material was antagonist, in patients mild to moderate essential hypertension. The study material was consisted of 28 patients (18 males, 10 females: mean age 54.9 ± 11.0 years). After a single-blind placebo run-in period of two weeks, felodipine was started at a dose of 5 mg once daily. If the sitting diastolic blood pressure (DBP) was not reduced to the target value of 90 mmHg, the dose was increased to 10 mg metoprolol 100 mg once daily for a further 2 weeks. In patients not responding to felodipine 10 mg, metoprolol 100 mg once daily was added to the active treatment. The mean values of blood pressure both standing (from 168 ± 2.5/101.7 ± 7.3 mmHg to 131.6 ± 9.7/81.9 ± 6.6 mmHg), and sitting (from 168.2 ± 17.6/100.8 ± 6.1 mmHg to 132.4 ± 11.3/82.7 ± 5.2 mmHg) positions were significantly reduced after felodipine treatment (p<0.001, p<0.001, p<0.001 and p<0.001). DBP was controlled with felodine 5 mg once daily in 40%, felodipine 10 mg once daily in 45%, and felodipine 10 mg + metoprolol 100 mg once daily in 10% of patients. Heart rate was not significantly changed during the active drug treatment. Drug was discontinued because of side effect (2 severe headache and 2 urticeria and palpitations) in 4 patients. We concluded that felodipine is an effective first-step antihypertensive drug in the treatment of patients with mild to made rate essential hypertension.